Validated Stability Indicating UHPLC Method for the Quantification of Escitalopram and Flupentixol in Pharmaceutical Formulation

Raj Patil; Rahul Keshav Godge

doi:10.52756/ijerr.2024.v38.004

Authors

Raj Patil Department of Quality Assurance, Pravara Rural College of Pharmacy, Loni BK-413736, Maharashtra, India https://orcid.org/0009-0002-0025-6383
Rahul Keshav Godge Department of Quality Assurance, Pravara Rural College of Pharmacy, Loni BK-413736, Maharashtra, India https://orcid.org/0000-0002-1275-9853

DOI:

https://doi.org/10.52756/ijerr.2024.v38.004

Keywords:

Escitalopram, forced degradation, flupentixol, UHPLC, validation

Abstract

To assess Escitalopram and flupentixol simultaneously, a verified method for ultra-phase high-performance liquid chromatography (UHPLC) has been developed to indicate stability. The method was thoroughly evaluated and met satisfactory criteria for precision, linearity, accuracy, limits on detection, robustness, and quantitation. The quantitation wavelength of 235 nm was determined. Linearity was successfully demonstrated across concentration ranges of 1–5 µg/ml of Escitalopram and 20-100 µg/ml of Flupentixol. UHPLC separations were conducted employing a Phenomenex L. C18 column measuring 100 x 4.6 mm and containing particles as small as 2.5 µm. To create the mobile phase, the 1% OPA and methanol (a pH of 4.2 with TEA) were combined in a volumetric ratio of 65:35v/v. Escitalopram and Flupentixol were effectively eluted at retention durations of 3.044 and 4.118 minutes, respectively, with the flow rate adjusted at 1.0 ml. The stability-indicating nature of the method was established through validated forced degradation studies. Which included hydrolysis under acidic and basic conditions, exposure to H2O2, thermal degradation, and photo-degradation. Escitalopram and Flupentixol exhibited 10 to 20% degradation under the specified conditions. Importantly, the process evaluated the two prescription drugs in detail with all degradation products generated during the forced degradation experiments. This developed method is characterized as straightforward, specific, and cost-effective, making it suitable for simultaneous estimating Escitalopram and Flupentixol in tabs dose forms.

References

Baghel, U.S., & Bindusar, K. (2019). Method Development and Validation of Stability Indicating RP-HPLC Method for Simultaneous Estimation of Escitalopram Oxalate and Clonazepam in Bulk and its Pharmaceutical Formulations. Journal of Drug Delivery and Therapeutics, 9(1s), 265-274. https://doi.org/10.22270/jddt.v9i1-s.2347

Bhavar, G., Dhamane, S., Gorde, P., & Shirapure, K. (2023). Comparative analysis of analytical method development and its validation for the simultaneous estimation of Bilastine and Montelukast Sodium in bulk and its tablet formulation by planar chromatography. Int. J. Exp. Res. Rev., 32, 387-397. https://doi.org/10.52756/ijerr.2023.v32.034

Beula, S.J., & Reddy, R.T. (2022). Stability Indicating RP-HPLC Method Development and Validation for The Simultaneous Estimation of Flupentixol and Melitracen in API from and Marketed Tablet Dosage form. Asian Journal of Pharmaceutical Analysis, 12(02), 23-29. https://doi.org/10.5958/2231–5675

Chugh, N. N., & Nagar, A. (2015). Simultaneous estimation method development as analytical method for flupentixol dihydrochloride and melitracen hydrochloride from their combine pharmaceutical dosage forms by RP-HPLC. Asian Journal of Pharmaceutical Technology & Innovation, 4(17), 81-86.

Damor, S.N., & Patel, D. (2017). Stability Indicating Chromatographic Method Development and Validation for The Simultaneous Estimation of Escitalopram Oxalate and Flupentixol in its Pharmaceutical Dosage Form by HPLC. World Journal of Pharmaceutical Research, 06(17), 549-566. https://doi.org/10.20959/wjpr201717-10219

Darthi, D., & Malathi, S. (2018). Simultaneous UV Spectrophotometric Method for Estimation of Escitalopram Oxalate and Flupentixol dihydrochloride in tablet dosage form. International Journal of ChemTech Research, 11(06), 134-138. https://doi.org/10.20902/IJCTR.2018.110618

Deshpande, M., Barge, S., Patil, K., Gaikwad, A., Barde, L., & Deshmukh, N. (2023). Stability indicating HPLC method development and validation of Fostemsavir in bulk and marketed formulations by implementing QbD approach. Int. J. Exp.Res. Rev., 30, 330-343. https://doi.org/10.52756/ijerr.2023.v30.030

Devakumar, D., & Sellappan, M. (2021). Development and Validation of Rp-Hplc Method for the estimation of Escitalopram Oxalate and Flupentixol Dihydrochloride in Combined dosage form and plasma. International Journal of Pharmacy and Pharmaceutical Sciences, 13(2), 61-66. https://doi.org/10.22159/ijpps.2021v13i2.30158

Dey, S. R., Dutta, S., & De, M. (2020). Neuro-Steroid Compound Found by GC-MS Analysis of The Methanolic Extract of The Leaves of Aegle marmelos (L) Corr. International Journal of Advancement in Life Sciences Research, 51-56. https://doi.org/10.31632/ijalsr.20.v03i04.006

Goulikar, S., & Tummala, P.R. (2022). Development and Validation of New Analytical Method for the Estimation of Flupentixol dihydrochloride in pure and pharmaceutical dosage form. World Journal of Pharmaceutical Research, 11(5), 986-1048. https://doi.org/10.20959/wjpr20225-23984

Kadam, M. M., & Singh, P.R. (2022). Development and Validation of Stability Indicating UHPLC Method for The Quantitative Estimation of Mirabegron and Solifenacin Succinate in dosage form. Journal of Pharmaceutical Negative Results, 13(07), 6727-6737. https://doi.org/10.47750/pnr.2022.13. S07.815

Kakde, R.B., & Stone, D.D. (2013). Stability-indicating RP-HPLC method for the determination of Escitalopram oxalate & Clonazepam. J. Chrom. Sco., 51(06), 490-495. https://doi.org/10.1093/chromsci/bms177

Kumar, S., & Kantipudi, R. (2022). Simultaneous Determination of Flupentixol and Nortriptyline HCL using Rp-Hplc with Pda Detector. International Journal of Applied Pharmaceutics, 14(6), 167-177. https://doi.org/10.22159/ijap.2022v14i6.46120

Maheshwari, D. G., & Patel, S.C. (2016). Development and Validation of UV Spectrometr and HPLC Method for Estimation of Escitalopram Oxalate and Flupentixol Dihydrochloride in combined dosage form. Asian Journal of Pharmaceutical Technology & Innovation, 04(17), 59-70.

Malathi, S., & Ananthi H. (2022). Development and validation of HPTLC method for the estimation of escitalopram oxalate and flupentixol dihydrochloride in pharmaceutical formulation. Research Journal of Pharmacy and Technology, 15(11), 5255-5259. https://doi.org/10.52711/0974-360X.2022.00885

Modi, D.K., & Sakhreliya, B.D. (2012). Development and Validation of Spectrophotometric Methods for Simultaneous Estimation of Escitalopram oxalate and Etizolam in their combined tablet dosage form. Journal of Pharmaceutical Science and Bioscientific Research, 2(5) 195- 200.

Nagar, A., & Naresh, N. (2015). Simultaneous estimation method development as analytical method for flupentixol dihydrochloride and melitracen hydrochloride from their combine pharmaceutical dosage forms by RP-HPLC. The Pharma Innovation Journal, 4(1), 81-86

Nimbokar, S.W., & Panchale, W.A. (2021). RP-HPLC method for simultaneous determination of escitalopram oxalate and flupentixol HCl in tablet dosage form. GSC Biological and Sciences, 14(01), 169 174. https://doi.org/10.30574/gscbps.2021.14.1.0004

Patel, D., & Singh, P. (2016). First Order Derivative Spectrophotometric Method for Estimation Escitalopram Oxalate and Flupentixol Dihydrochloride in Pharmaceutical Dosage Form. Indo American Journal of Pharmaceutical Research, 6(2), 4544-4553.

Stefan, B. (2022). HPLC determination of Escitalopram in tablet dosage forms. Bulgarian Pharmaceutical Union, Sofia, Bulgaria, 69(01), 21-24. https://doi.org/10.3897/pharmacia.69.e77878.